BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Sep 06, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Twynsta telmisartan/amlodipine: Phase III data

In a double-blind Phase III trial in 858 patients with severe hypertension, an 80/10 mg formulation of Twynsta telmisartan/amlodipine met the primary endpoint of a significantly greater reduction from baseline in mean seated SBP at week 8 vs. 80 mg telmisartan alone (p<0.0001) and 10 mg amlodipine alone (p=0.0002). Additionally, 46% of...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >